Current Headlines

  1. Drug Development Outsourcing Outpaces Internal Spending But Remains Tactical And Reactive, According To Tufts Center For The Study Of Drug Development
    3/5/2019

    Drug sponsors spend more on contract research organizations (CROs) to help develop new medicines than they do on internal staff and infrastructure, but outsourcing practices remain inconsistent and highly customized, inviting inefficiency and unsystematic management practice, according to an analysis recently completed by the Tufts Center for the Study of Drug Development

  2. MaxCyte Announces Multi-Drug Clinical & Commercial Agreement With Kite, A Gilead Company
    3/1/2019

    MaxCyte, the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement

  3. AbCellera And Denali Therapeutics Sign Expanded Multi-Year, Multi-Target Deal To Discover Therapeutic Antibodies For Neurological Diseases
    2/28/2019

    AbCellera recently announced an expanded collaboration with Denali Therapeutics Inc. to discover antibodies as therapies for neurological indications

  4. Ascendis Pharma Announces Orphan Drug Designation Granted For TransCon CNP As Treatment For Achondroplasia
    2/28/2019

    Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TransCon CNP, a long-acting prodrug of C-type natriuretic peptide (CNP) in development for children with achondroplasia

  5. Rare Disease Repurposing Datathon From Elsevier And The Pistoia Alliance Reveals New Candidates For Potential Treatment Of Chronic Pancreatitis
    2/28/2019

    A unique non-profit and private partnership using a datathon and an AI-powered technology platform has identified new repurposable drug candidates to treat a painful chronic disease affecting about a million people globally and for which there is no current treatment

  6. Healx Pushing New Drug Development Model In Rare Diseases With Barth Syndrome Foundation
    2/28/2019

    Healx, a Cambridge (UK) technology company, today announced a collaboration with Boston Children’s Hospital and Barth Syndrome Foundation (BSF) to advance promising therapeutic compounds using a novel approach that will accelerate drug discovery for applications in Barth syndrome, a life-threatening, genetic mitochondrial disease

  7. NanoViricides Reaches An Agreement On Terms Of License For Shingles Virus Drug Development
    2/26/2019

    NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), reported today that it has reached an agreement on the terms of the license for the drug development against VZV, the virus that causes chickenpox in children and shingles in adults

  8. Reprogramming The Wonder Drug Rapamycin Allows Creation Of New Small-Molecule Drugs
    2/26/2019

    Most current medicines are derived from naturally occurring small molecules. Yet the lack of a systematic method for producing diverse nature-inspired small molecules has prevented the development of a wider range of new medications

  9. Artificial Lung Cancer Tissue Could Help Find New Drug Treatments
    2/25/2019

    A 3D hydrogel created by researchers in University Professor Molly Shoichet’s (ChemE, IBBME) lab is helping University of Ottawa researchers to quickly screen hundreds of potential drugs for their ability to fight highly invasive cancers

  10. Aptose Biosciences Submits IND Application For CG-806
    2/25/2019

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has submitted an Investigational New Drug (IND) application for CG-806 to the U.S. Food and Drug Administration (FDA) requesting approval to initiate its Phase 1 clinical trial program